At the beginning of the week, the pharmaceutical company Stayble Therapeutics achieved an important milestone in the phase IIb study with STA363 when 100 patients had completed their 6-month visit. This means that Stayble has secured all the necessary data required to evaluate the study's primary endpoint - to show pain reduction in patients with chronic disc-related back pain. Stayble is now one step closer to presenting top-line data, which is expected to take place during the fourth quarter of 2023.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/02/stayble-is-done-with-the-6-month-follow-up/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/stayble-therapeutics/r/biostock-stayble-is-done-with-the-6-month-follow-up,c3715252

(c) 2023 Cision. All rights reserved., source Press Releases - English